Literature DB >> 21727111

The need for vigilance: the case of a false-negative newborn screen for cystic fibrosis.

Christina T Dunn1, Mary M Skrypek, Amy L R Powers, Theresa A Laguna.   

Abstract

Cystic fibrosis (CF) is the most common life-limiting recessive genetic disorder in the white population. CF is caused by abnormalities in the gene that codes for the cystic fibrosis transmembrane conductance regulator protein (CFTR) and may result in severe chronic lung disease, poor growth, and malnutrition. Physicians often do not consider CF in the differential diagnosis of an infant with failure to thrive in the presence of a negative newborn screening (NBS) result. In Minnesota, newborn infants are screened for CF by immunoreactive trypsinogen (IRT) testing followed by DNA analysis if the IRT screen result is abnormal. All positive NBS results are followed by confirmatory sweat-testing by pilocarpine iontophoresis. We present here the case of a 1-month-old white boy with failure to thrive, chronic diarrhea, and severe malnutrition. Minnesota state CF NBS results were negative at birth (IRT: 43 ng/mL [96% cutoff value: 52 ng/mL]). Clinical symptoms resulted in sweat-testing by Gibson-Cooke pilocarpine iontophoresis at 1 month of age, and the result was positive (102 mmol Cl(-)/L [normal: ≤30 mmol Cl(-)/L]). CFTR mutation analysis confirmed a homozygous f508del genotype, and stool pancreatic elastase testing revealed severe exocrine pancreatic insufficiency. This case represents the first known false-negative result in Minnesota since the initiation of NBS for CF in 2006, which illustrates the importance of considering CF in the evaluation of an infant with failure to thrive and symptoms of malabsorption, regardless of NBS results.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21727111      PMCID: PMC8202520          DOI: 10.1542/peds.2010-0286

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  16 in total

1.  Failure to recognize the association of cystic fibrosis and metabolic alkalosis.

Authors:  Lawrence E Kurlandsky
Journal:  Clin Pediatr (Phila)       Date:  2002 Nov-Dec       Impact factor: 1.168

2.  False negative cystic fibrosis newborn screen.

Authors:  Joseph Michael Collaco; Susan R Panny; Ada Hamosh; Peter J Mogayzel
Journal:  Clin Pediatr (Phila)       Date:  2010-03       Impact factor: 1.168

3.  Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.

Authors:  Marci K Sontag; Keith B Hammond; Julian Zielenski; Jeffrey S Wagener; Frank J Accurso
Journal:  J Pediatr       Date:  2005-09       Impact factor: 4.406

4.  A prospective randomized trial of early diagnosis and treatment of cystic fibrosis: a unique ethical dilemma.

Authors:  N Fost; P M Farrell
Journal:  Clin Res       Date:  1989-09

5.  Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group.

Authors:  P M Farrell; M R Kosorok; M J Rock; A Laxova; L Zeng; H C Lai; G Hoffman; R H Laessig; M L Splaingard
Journal:  Pediatrics       Date:  2001-01       Impact factor: 7.124

6.  Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen.

Authors:  Molly Kloosterboer; Gary Hoffman; Michael Rock; William Gershan; Anita Laxova; Zhanhai Li; Philip M Farrell
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

7.  Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.

Authors:  Anne Marie Comeau; Richard B Parad; Henry L Dorkin; Mark Dovey; Robert Gerstle; Kenan Haver; Allen Lapey; Brian P O'Sullivan; David A Waltz; Robert G Zwerdling; Roger B Eaton
Journal:  Pediatrics       Date:  2004-06       Impact factor: 7.124

8.  Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening.

Authors:  Peter D Sly; Siobhain Brennan; Catherine Gangell; Nicholas de Klerk; Conor Murray; Lauren Mott; Stephen M Stick; Philip J Robinson; Colin F Robertson; Sarath C Ranganathan
Journal:  Am J Respir Crit Care Med       Date:  2009-04-16       Impact factor: 21.405

9.  Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations.

Authors:  K B Hammond; S H Abman; R J Sokol; F J Accurso
Journal:  N Engl J Med       Date:  1991-09-12       Impact factor: 91.245

10.  Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.

Authors:  Drucy Borowitz; Karen A Robinson; Margaret Rosenfeld; Stephanie D Davis; Kathryn A Sabadosa; Stephanie L Spear; Suzanne H Michel; Richard B Parad; Terry B White; Philip M Farrell; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

View more
  4 in total

Review 1.  False negative newborn screen and neonatal cholestasis in a premature child with cystic fibrosis.

Authors:  J F Heidendael; M M Tabbers; I De Vreede
Journal:  Eur J Pediatr       Date:  2013-08-15       Impact factor: 3.183

2.  Newborn Screening Saves Lives but Cannot Replace the Need for Clinical Vigilance.

Authors:  F Neemuchwala; M Taki; E Secord; S Z Nasr
Journal:  Case Rep Pediatr       Date:  2018-07-02

3.  Dehydrated patient without clinically evident cause: A case report.

Authors:  Federica Palladino; Maria Cristina Fedele; Marianna Casertano; Laura Liguori; Tiziana Esposito; Stefano Guarino; Emanuele Miraglia Del Giudice; Pierluigi Marzuillo
Journal:  World J Clin Cases       Date:  2020-10-26       Impact factor: 1.337

4.  Clinical complications in children with false-negative results in cystic fibrosis newborn screening.

Authors:  Katarzyna Zybert; Urszula Borawska-Kowalczyk; Lukasz Wozniacki; Malwina Dawidziuk; Mariusz Ołtarzewski; Dorota Sands
Journal:  J Pediatr (Rio J)       Date:  2021-12-22       Impact factor: 2.990

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.